Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092287 · ClinicalTrials.gov registry record · Phase 3
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
A Phase 3 study, sponsored by Ipsen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT00092287 is a Phase 3 study that was terminated before completion, run by Ipsen. The registered enrollment target is 4 participants.
The verdict
NCT00092287, a Phase 3 study, was terminated before completion, sponsored by Ipsen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.
Interventions
- DRUG lanreotide Autogel (somatostatin analogue)
- DRUG Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2004-07 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00092287
The ClinicalTrials.gov registry entry for NCT00092287 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lanreotide Autogel (somatostatin analogue) is the first listed.
NCT00092287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00092287 about?
NCT00092287 is a clinical study titled "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome". The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.
What is the current status of trial NCT00092287?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2004-07. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00092287?
The interventions under investigation include: lanreotide Autogel (somatostatin analogue) (DRUG), Sandostatin long acting release (LAR) Depot (somatostatin analogue) (DRUG).
Who is sponsoring clinical trial NCT00092287?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.